The NYU Grossman School of Medicine’s working group on Pediatric Gene Therapy and Medical Ethics formed in the fall of 2019 to address and propose recommendations to issues involving gene-based therapies in pediatric populations, including research activities.
Bright light therapy (10,000 lux intensity for 30 minutes twice daily) and a low intensity control light showed similar efficacy in treatment of depression associated with Parkinson’s disease; the bright light therapy showed some advantages in improving subjective quality of sleep.
Longer lifetime exposure to endogenous estrogen and menopausal estrogen replacement were associated with better cognitive status in older adult women. Women who initiated estrogen therapy early (within five years of the onset of menopause) showed higher cognitive test scores than those who started later.
In a randomized clinical trial conducted at 27 hospitals in four countries, researchers found that the addition of an antistaphylococcal beta-lactam to vancomycin or daptomycin (99% received vancomycin) did not lead to improved outcomes in MRSA bacteremia. The trial was stopped early because of safety concerns, including a higher risk of acute kidney injury in the combination group.
In three subgroups of coronary artery disease patients with atrial fibrillation, apixaban plus a P2Y12 inhibitor provided superior safety and similar efficacy outcomes as treatment with warfarin, aspirin, or both for six months.
Research suggests some hip fracture surgery patients experience better outcomes after the procedure with a longer post-acute stay. Recovery also is easier when these patients do not have to engage in intensive physical therapy initiated immediately after surgery.
A meta-analysis that included more than 18,000 patients from 70 clinical centers in 36 countries found that neuraminidase inhibitors started at the beginning of hospitalization in patients with clinically suspected or laboratory-confirmed influenza A reduced the length of hospitalization by 19%.
An individual-participant meta-analysis of prospective studies revealed menopausal hormone therapy associated with an elevation in the risk of breast cancer, with the highest risks associated with daily combined therapy.